Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

This study has been completed.
Information provided by:
Celgene Identifier:
First received: September 13, 2004
Last updated: September 22, 2009
Last verified: September 2009